Bank of New York Mellon Corp Has $44.47 Million Holdings in Moderna, Inc. $MRNA

Bank of New York Mellon Corp cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 16.0% in the second quarter, HoldingsChannel reports. The firm owned 1,611,959 shares of the company’s stock after selling 306,289 shares during the period. Bank of New York Mellon Corp’s holdings in Moderna were worth $44,474,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of MRNA. Corton Capital Inc. bought a new stake in Moderna during the second quarter valued at about $475,000. State of Michigan Retirement System lifted its position in shares of Moderna by 0.8% during the 2nd quarter. State of Michigan Retirement System now owns 92,541 shares of the company’s stock worth $2,553,000 after purchasing an additional 700 shares during the last quarter. GAM Holding AG bought a new stake in Moderna during the 2nd quarter valued at approximately $276,000. Amalgamated Bank boosted its stake in Moderna by 0.6% during the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after purchasing an additional 408 shares during the period. Finally, Assetmark Inc. grew its holdings in Moderna by 137.7% in the 2nd quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock valued at $36,000 after buying an additional 752 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $26.41 on Wednesday. Moderna, Inc. has a 52-week low of $23.04 and a 52-week high of $48.92. The firm has a market capitalization of $10.32 billion, a PE ratio of -3.27 and a beta of 2.02. The company’s fifty day moving average price is $25.86 and its two-hundred day moving average price is $27.11.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm’s revenue was down 45.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. Analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. Bank of America cut their price target on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a report on Monday. Leerink Partners dropped their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. Citigroup reduced their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. Morgan Stanley raised their price target on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $36.14.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.